129042-60-0

Basic information

• Product Name: 3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid
• Synonyms: 3-AMINO-3-BENZO[1,3]DIOXOL-5-YL-PROPIONIC ACID;3-Amino-3-(3,4-methylendioxyphenyl)propionic acid
• CAS NO: 129042-60-0
• Molecular Formula: C₁₀H₁₁NO₄
• Molecular Weight: 209.2
• Mol File: 129042-60-0.mol

Chemical Properties

• Boiling Point: 381.9 °C at 760 mmHg
• Flash Point: 184.8 °C
• Appearance: /
• Density: 1.404g/cm³
• Vapor Pressure: 1.63E-06mmHg at 25°C
• Refractive Index: 1.61
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid(129042-60-0)
• EPA Substance Registry System: 3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid(129042-60-0)

Safety Data

• Hazardous Substances Data: 129042-60-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid is used as a key intermediate in the synthesis of pharmaceutical drugs for its ability to be incorporated into various drug molecules, enhancing their therapeutic effects.
Used in Antifungal Applications:
In the field of antifungal research, 3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid is used as an active compound for its potential to combat fungal infections, providing a new avenue for the development of antifungal agents.
Used in Antibacterial Applications:
3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid is utilized as an antibacterial agent, leveraging its potential to inhibit bacterial growth, which is crucial in the ongoing battle against antibiotic-resistant strains.
Used in Enzyme Inhibition:
3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid is employed in the development of enzyme inhibitors, where it can be used to modulate the activity of specific enzymes, offering potential therapeutic benefits in various diseases where enzyme dysregulation is implicated.
Overall, 3-Amino-3-benzo[1,3]dioxol-5-yl-propionic acid is a multifaceted chemical with a broad spectrum of potential applications, particularly in drug development and medicinal chemistry, where its unique structural features and biological activities can be harnessed to address various health challenges.

InChI:InChI=1/C10H11NO4/c11-7(4-10(12)13)6-1-2-8-9(3-6)15-5-14-8/h1-3,7H,4-5,11H2,(H,12,13)

Upstream product

• 120-57-0 piperonal 
• 631-61-8 ammonium acetate 
• 141-82-2 malonic acid 
• 7803-49-8 hydroxylamine 
• 2373-80-0 3,4-methylenedioxy-trans-cinnamic acid 

Downstream Products

• 138621-69-9 5,6-methylenedioxy-3-trifluoroacetylaminoindan-1-one 
• 149498-94-2 ethyl 3-amino-3-(1,3-benzodioxol-5-yl)-propanoate hydrochloride 
• 72071-75-1 (R)-3-amino-3-(piperon-3-yl)propanoic acid 
• 148502-20-9 5,6-methylenedioxy-1-oxoindan-3-ylammonium chloride 
• 149519-82-4 ethyl β-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-1,3-benzodioxole-5-propanoate 
• 858555-40-5 m-[4-oxo-4-(4-Boc-piperazin-1-yl)butyrylamino]benzoyl-β-(3,4-methylenedioxyphenyl)-β-alanine 

Relevant articles and documents

Kinetic resolution of aromatic β-amino acids by ω-transaminase

Racemic aromatic β-amino acids have been kinetically resolved into (R)-β-amino acids with high enantiomeric excess (>99%) by a novel ω-TA with ca. 50% conversion.

METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES

A method for preparing indenoisoquinoline derivatives represented by the following formula (I) is disclosed, which comprises the following steps: (A) providing a first reactant represented by the following formula (II) and a second reactant represented by the following formula (III): wherein, R1, R3, A, X, Y, Z, m and n are defined in the specification; and (B) reacting the first reactant represented by the formula (II) and the second reactant represented by the formula (III) in a solvent and selectively adding R2NH2 therein, to obtain the indenoisoquinoline derivatives represented by the formula (I).

An efficient new enzymatic method for the preparation of β-aryl-β-amino acid enantiomers

An efficient synthesis of β-aryl-β-amino acid enantiomers has been developed via the lipase-catalysed enantioselective hydrolysis of the corresponding racemic ethyl esters in an organic solvent. High enantioselectivities (E >100) were observed when the lipase PS-catalysed reactions were performed with H2O (0.5 equiv) in diisopropyl ether at 45 °C. The products could be easily separated and were obtained in good yields of ≥40%.

3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO

The present invention is to provide an n-alkyl 3-amino-3-arylpropionate represented by the formula (I): wherein Ar1 represents an aryl group which may have a substituent(s), provided that a phenyl group and 4-methoxyphenyl group are excluded, R1 represents an n-propyl group or an n-butyl group, and a process for preparing the same, and its optically active compound and an optically active (S or R)-3-amino-3-arylpropionic acid represented by the formula (III-a): wherein Ar represents an aryl group which may have a substituent(s), and * represents an asymmetric carbon, and a process for preparing an optically active n-alkyl (R or S)-3-amino-3-arylpropionate represented by the formula (IV-a): wherein Ar and R1 have the same meanings as defined above, * represents an asymmetric carbon, provided that it has a reverse absolute configuration to the compound of the formula (III-a).

Heterocyclic anti-epileptogenic agents and methods of use thereof

Methods and compounds, such as β-heterocyclic-β-amino acids, useful for the inhibition of epileptogenesis are disclosed. Methods for preparing and using the β-heterocyclic-β-amino acids of the invention are also described.

Aromatic β-amino acids as Asp-Phg mimics in LDV derived VLA-4 antagonists

Aromatic β-amino acid esters 2a-h were prepared in racemic and enantiomerically pure form by the Radionow reaction or based on the method described by Davis and used as mimics of the Asp-Phg C-terminus in LDV derived VLA-4 antagonists. As a promising β-am

Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308

Although intravenously administered antiplatelet fibrinogen receptor (GPIIb/IIIa) antagonists have become established in the acute-care clinical setting for the prevention of thrombosis, orally administered drugs for chronic use are still under development. Herein, we present details from our exploration of structure-activity surrounding the prototype fibrinogen receptor antagonist RWJ-50042 (racemate of 1), which was derived from a unique approach involving the γ-chain of fibrinogen (Hoekstra et al. J. Med. Chem. 1995, 38, 1582). Our analogue studies culminated in the discovery of RWJ-53308 (2), a potent, orally active GPIIb/IIIa antagonist. To progress from RWJ-50042 to a suitable candidate for clinical development, we conducted a series of optimization cycles that employed solid-phase parallel synthesis for the rapid, efficient preparation of nearly 250 analogues, which were assayed for fibrinogen receptor affinity and inhibition of platelet aggregation induced by four different activators. This strategy produced several promising analogues for advanced study, including 3-(3,4- methylenedioxybenzene)-β-amino acid analogue 3 (significant improved in vivo potency) and 3-(3-pyridyl)-β-amino acid 2 (significantly improved potency, oral absorption, and duration of action). In dogs, 2 displayed significant ex vivo antiplatelet activity on oral administration at 1.0 mg/kg, 16% systemic oral bioavailability, minimal metabolic transformation, and an excellent safety profile. Additionally, 2 was found to be efficacious in three in vivo thrombosis models: canine arteriovenous (AV) shunt (0.01-0.1 mg/kg, iv), guinea pig photoactivation-induced injury (0.3-3 mg/kg, iv), and guinea pig ferric chloride-induced injury (0.3-1 mg/kg, iv). On the basis of its noteworthy preclinical data, RWJ-53308 (2) was selected for clinical evaluation.

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists

Our initial orally active fibrinogen receptor antagonist benzamidinopentanoyl (BAP) series which was discovered through truncation of our iv antiplatelet agent (SC-52012) demonstrated modest oral activity in canine studies (ethyl [5-(4-amidinophenyl)penta

One-Pot Cyclization of Alkoxy-3-Aminoindan-1-ones.

3-Amino-3-alkoxyphenylpropionic acids, prepared from alkoxybenzaldehydes, are cyclized in one step into 3-aminoindan-1-ones using trifluoroacetic acid and trifluoroacetic anhydride. Key Words: One-pot cyclization; Aminoindanones; Electrodonating substitue